Approved – Page 8

Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors

4 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A and B, inhibitors, Nordisk, once-daily, Prophylactic treatment, United States Food and Drug Administration

Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab

Breakthrough in Familial Chylomicronemia Syndrome: FDA Approves Ionis’ Tryngolza as First Treatment

4 months ago talkbio0Tagged Approved, Familial chylomicronemia syndrome, Genetic Hyperlipidemia, Lipid-lowering therapy, Pancreatitis, Acute, TRYNGOLZA, United States Food and Drug Administration

Familial Chylomicronemia Syndrome (FCS), Ionis Tryngolza, FDA Approval, Rare Genetic Hyperlipidemia, Acute Pancreatitis, Lipid-Lowering Therapy

FDA Approves Humacyte’s Symvess ATEV: A Breakthrough in Regenerative Medicine for Vascular Trauma Treatment

4 months ago talkbio0Tagged Approved, ATEV, Humacyte, lab-grown blood vessels, Regenerative Medicine, Symvess, United States Food and Drug Administration, vascular trauma

Humacyte, FDA approval, Symvess ATEV, regenerative medicine, vascular trauma, lab-grown blood vessels

FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder

4 months ago talkbio0Tagged Approved, Familial chylomicronemia syndrome, Metabolic Diseases, Olezarsen, TRYNGOLZA, United States Food and Drug Administration

FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

4 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

4 months ago talkbio0Tagged Approved, Cell Therapy, Mesenchymal Stromal Cell Therapy, Mesoblast, Pediatric brand name, Ryoncil, SR-aGVHD, Steroid-Refractory Acute Graft-Versus-Host Disease, United States Food and Drug Administration

Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy